Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Wave Life Sciences, Inc. - Common Stock (NQ:WVE)

3.755 -0.025 (-0.66%)
Delayed Quote Updated: 11:05 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Wave Life Sciences Announces FDA Feedback Supports Registrational Pathway for WVE-006 (RNA Editing) in AATD
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces GSK’s Selection of siRNA program to Transition to GSK for Further Development
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business Officer
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
Wave Life Sciences (NASDAQ:WVE) Plunges After Q2 Revenue Miss ↗
Via Chartmill
Wave Life Sciences (NASDAQ:WVE) Beats Q1 Estimates as Obesity Program Accelerates ↗
Via Chartmill
News headline image
Wave Life Sciences Announces Completion of Redomiciliation to Delaware
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript ↗
WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials. 
Via The Motley Fool
Topics Earnings
News headline image
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript ↗
WVE-007 obesity candidate shows 16.5% visceral fat improvement in early trials. 
Via The Motley Fool
Topics Earnings
News headline image
WAVE Life Sciences Q2 Earnings Call Highlights ↗
WAVE Life Sciences (NASDAQ:WVE) reported a wider second-quarter loss as it increased investment in its obesity and RNA-editing programs, while outlining several clinical and regulatory milestones... 
Via MarketBeat
Topics Earnings
News headline image
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at Upcoming Investor Conferences
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Wave (WVE) Q1 2026 Earnings Call Transcript ↗
Wave (WVE) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Wave (WVE) Q2 2025 Earnings Call Transcript ↗
Wave (WVE) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Wave (WVE) Q1 2025 Earnings Call Transcript ↗
Wave (WVE) Q1 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Leads Shift Toward Pipeline-Driven Valuation in Biotech Sector
Via Investor Brand Network
Topics Intellectual Property
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
Via Investor Brand Network
News headline image
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
News headline image
Advancing Drug Pipelines Drive Biotech Valuations as Scientific Progress Gains Financial Recognition
From BioMedWire
Via GlobeNewswire
News headline image
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
From Wave Life Sciences USA, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.